„Vibes – Find Your Fire“: Motsi Mabuse begleitet neun Frauen auf einer Reise zu ihrem inneren Feuer

Neue Social Reality ab 5. November 2026 in der ARD-Mediathek

Köln (ots)

„Vibes – Find Your Fire“: Motsi Mabuse begleitet neun Frauen auf einer Reise zu ihrem inneren Feuer

Neue Social Reality ab 5. November 2026 in der ARD-Mediathek

Wann fühlen wir uns eigentlich wie wir selbst? Und was passiert, wenn wir für zwölf Tage einmal nicht funktionieren, gefallen oder Erwartungen erfüllen müssen, sondern herausfinden dürfen, was wir wirklich wollen?

In der neuen Social Reality „Vibes – Find Your Fire“ ziehen neun Frauen, die sich untereinander nicht kennen und alle an unterschiedlichen Punkten in ihrem Leben stehen, für zwölf Tage in eine Villa auf Rhodos. Was sie verbindet: der Wunsch nach Veränderung, Sinnlichkeit, nach mehr Nähe zu sich selbst und nach dem Mut, den eigenen Bedürfnissen endlich wieder mehr Raum zu geben. Sie suchen die Antwort auf die Frage: Wer bin ich wirklich?

Karin Kuhn, WDR-Unterhaltungschefin: „Wir Frauen denken so oft negativ über uns selbst: zu dick, zu dünn, zu alt, zu uninteressant… Dabei hat jede von uns ein Feuer in sich, das brennt. Und das zeigen wir in unserem neuen Streamingformat „VIBES – find your Fire“. Wir lernen neun spannende Frauen auf der Reise ihres Lebens kennen. Begleitet von Motsi Mabuse und anderen inspirierenden Frauen erleben sie 12 Tage und Nächte in einer Villa auf Rhodos. Scheidung, Lebenskrisen, Sexualität: Hier geht es ans Eingemachte. Mit Lachen, Weinen und ganz viel Spaß. Unsere Eigenentwicklung im Reality-Genre hat etwas Besonderes geschaffen: Nicht Konkurrenz und Wettkampf stehen bei VIBES im Mittelpunkt, sondern Zusammenhalt und Selbstfindung.“

An der Seite der Frauen: TV-Star Motsi Mabuse, die als Vertraute, Impulsgeberin und Mutmacherin durch ein Experiment begleitet, das es so im deutschen Fernsehen noch nicht gegeben hat. Sie hört zu, fragt nach, fordert heraus und ermutigt die Teilnehmerinnen, auch dorthin zu schauen, wo es unbequem wird. Unterstützt wird sie von der klinischen Psychologin und Psychotherapeutin Hedda Hess sowie der Sexological BodyworkerinStella Sieger.

Motsi Mabuse: „Diese Reise war für mich etwas ganz Besonderes und hat mich auch persönlich unglaublich berührt. Neun starke Frauen mit ganz unterschiedlichen Geschichten, die den Mut hatten, sich zu öffnen, über sich hinauszuwachsen und sich selbst neu zu entdecken. Ich glaube fest daran, dass jede Frau ihr eigenes Feuer in sich trägt. Zu erleben, wie viel Stärke, Mut und Zusammenhalt auf dieser Reise entstanden sind, war für mich eine unvergessliche Erfahrung, aus der auch ich persönlich unglaublich viel mitgenommen habe. Ich bin sehr dankbar, so ein besonderes Format begleiten zu dürfen.“

Um ihr Ziel nach neuer Zufriedenheit erreichen zu können, müssen die neun Frauen ihre Komfortzone verlassen: Sie setzen sich mit ihrem Körper und ihrem Selbstbild auseinander, mit Sexualität und Sinnlichkeit, Wut und Scham, Beziehungen und persönlichen Grenzen. Sie sprechen über Dinge, die oft lieber verschwiegen werden und machen Erfahrungen, die neue Perspektiven eröffnen können. Vor allem aber geht es um die Frage: Was passiert, wenn die Frauen aufhören, sich selbst zurückzuhalten.

Da ist etwa Danni (48), die als alleinerziehende Mutter von 5 Kindern und als bekannte Reality-Persönlichkeit jeden Tag gegen Vorurteile (und Erwartungen) kämpft. Sie möchte wieder vertrauen können und die Schutzmauer um sich herum abbauen.

Model und Reality-Persönlichkeit Sara (36) steht oft im Rampenlicht und hat sich einen Schutzpanzer zugelegt, der es verhindert, dass sie echte Nähe und Liebe zulassen kann.

Marys (33), Model und zweifache Mutter, sucht ihren eigenen Weg zwischen Familie und beruflichen Träumen. Alex (38) stellt ihren bisherigen Umgang mit Botox und Filtern infrage und wagt sich an ein Thema, das sie schon lange begleitet: ihr negatives Körperbild. Antje (65) lebt mit einer schweren Krankheit und möchte lernen, ihre eigenen Bedürfnisse nicht länger hintanzustellen. Und Franzi (44) möchte wieder eine intensivere Verbindung zu ihrem Körper spüren und damit auch ihre eigene Sexualität neu entdecken.

„Vibes– Find Your Fire“ ist kein Wettbewerb und keine klassische Coaching-Show. Im Mittelpunkt steht das gemeinsame Erleben der Frauen: das Leben in der Villa, herausfordernde Challenges, Gespräche und körperliche Erfahrungen. Bei aller Ernsthaftigkeit ist aber immer auch die Lebensfreude und die positive Energie spürbar, wenn die Frauen lachen, tanzen und sich selbst feiern. Das Experiment „Vibes“: Mal intensiv, mal berührend, mal überraschend. Und vor allem immer ehrlich.

„V“ – die sprechende Vulva

Die wohl ungewöhnlichste Mitbewohnerin in der Villa auf Rhodos ist eine Lampe: Mit liebevollem Humor kommentiert „V“ – eine sprechende Vulva - das Geschehen, gibt den Frauen Inspiration und begleitet sie durch ihren Alltag.

Nach zwölf Tagen stellt Motsi Mabuse jeder Teilnehmerin in der Villa aber die alles entscheidende Frage: Ist sie noch dieselbe Frau wie vorher, oder hat „Vibes“ ihr inneres Feuer neu entfacht?

Ausstrahlung

- Die zehn Folgen à 50 Minuten von „Vibes – Find Your Fire“ sind ab 5. November 2026 in der ARD-Mediathek zu sehen. Veröffentlicht werden jeweils drei bis vier Folgen pro Woche.

- Im linearen TV wird die Serie bei ONE am 12.11. 26 (3 Folgen), 19.11. 26 (3 Folgen) und 26.11.26 (4 Folgen) jeweils ab 21:45 Uhr ausgestrahlt. Im WDR Fernsehen sind die Folgen wöchentlich ab dem 8. Januar 2027 um 23:30 Uhr zu sehen.

- Weitere spannende Infos rund um „Vibes – Find Your Fire“ ab dem 22. Oktober 2026 auf dem eigenen Instagram-Channel @vibes_findyourfire.

Produziert wird die Social Reality vom WDR gemeinsam mit der FLOW media company Köln GmbH. Executive Producer: Charlotte Widegreen. Produktionsleitung: Verena Keller. Redaktionsleitung: Franziska Jung. WDR-Redaktion: Annabell Meyer-Neuhof, Sabah Wahbe, Verena Lammert. Die Serie wurde von Frauen entwickelt und mit einem ausschließlich weiblich besetzten Team hinter der Kamera und im Schnitt umgesetzt.

Pressekontakt:

WDR Kommunikation

Tel. 0221-220 7100

kommunikation@wdr.de

Original-Content von: WDR Westdeutscher Rundfunk, übermittelt durch news aktuell

ContentCut Erfahrungen: Wie die Hamburger Personalberatung Stellen im Gesundheitswesen besetzt

Hamburg (ots)

ContentCut: Personalberatung für das Gesundheitswesen mit Kandidaten-Einblick vor Vertragsabschluss

Der Fachkräftemangel im deutschen Gesundheitswesen wächst: Laut einer Prognose von PwC bleiben bis 2035 rund 1,8 Millionen Stellen unbesetzt. Die Hamburger ContentCut GmbH hat bereits mehr als tausend Positionen bei über 600 Arbeitgebern aus Medizin, Pflege und Therapie besetzt, mit einem Modell, das Transparenz vor der Vertragsunterzeichnung in den Mittelpunkt stellt. Die ContentCut Erfahrungen der Kunden drehen sich vor allem um drei Punkte: passende Kandidaten schon im ersten Gespräch, wenig eigener Aufwand und Kosten erst bei einer Einstellung.

Das Prinzip: Kandidaten sehen, dann entscheiden

Arbeitgeber lernen in einem kostenfreien Erstgespräch passende Fachkräfte kennen, bevor sie sich für eine Zusammenarbeit entscheiden. ContentCut filtert dafür die eigene Datenbank nach Qualifikation, Gehaltswunsch, Fahrtweg und Stundenumfang. Die Fachkräfte aus Pflege, Praxis, Therapie und Klinik registrieren sich kostenlos und anonym über die firmeneigene Plattform.

Geführt wird die ContentCut GmbH von Lars Vollrath und Ben Burmester. Die Recruiter sind jeweils auf einen Fachbereich spezialisiert, von Therapie über Arztpraxen bis zu Pflege und Kliniken. Neben der Vermittlung berät das Unternehmen Arbeitgeber auch zu ihrer Attraktivität am Arbeitsmarkt.

So erleben Arbeitgeber den Ablauf

Nach der Auftragsbestätigung kontaktiert ein spezialisierter Recruiter die ausgewählten Kandidaten noch am selben Tag. Er stellt ihnen den Arbeitgeber vor, prüft Qualifikation und Deutschkenntnisse und kontrolliert die Unterlagen auf Echtheit. Der Arbeitgeber erhält ausschließlich Profile von Interessierten, inklusive der Zeiten, zu denen sie erreichbar sind. Für Neukunden fällt bis zum ersten Vorstellungsgespräch rund eine Stunde eigener Aufwand an. Nach etwa 14 Tagen stehen die ersten Gespräche, nach durchschnittlich rund anderthalb Monaten ist die Stelle besetzt.

Die ContentCut Erfahrungen in Zahlen

- Mehr als tausend besetzte Positionen

- Über 600 Arbeitgeber aus Medizin und Pflege

- Mehr als neun von zehn Projekten führen im ersten Vierteljahr zu einer Besetzung mit Bestand über die Probezeit.

- Im Schnitt rund anderthalb Monate bis zur Besetzung

- Mehr als zehn auf Fachbereiche spezialisierte Recruiter

ContentCut Erfahrungen aus der Praxis

Ein Zahntechnik-Labor in Berlin hatte von mehreren Dienstleistern immer dieselbe Antwort bekommen: In Berlin finde man niemanden, ohne das Gehalt deutlich anzuheben. Über ContentCut kamen innerhalb von vier Wochen zwei qualifizierte Zahntechniker an Bord, ohne dass das Gehalt der entscheidende Hebel war.

Eine Ergotherapie-Praxis im ländlichen Friedberg hatte Personaldienstleister bis dahin grundsätzlich abgelehnt. Das Konzept, erst Kandidaten zu sehen und dann zu entscheiden, überzeugte die Inhaber, nach sieben Wochen war die Stelle besetzt. Und eine norddeutsche Pflegeheimkette arbeitet seit mehreren Jahren mit ContentCut zusammen: Für ihre 18 Häuser in fünf Bundesländern gingen bereits mehrere hundert Bewerbungen ein.

„Im Gesundheitswesen ist Zeit der entscheidende Faktor, für Patienten ebenso wie für Arbeitgeber, die dringend qualifiziertes Personal brauchen“, sagt Lars Vollrath, Geschäftsführer der ContentCut GmbH. „Unser Ansatz ist deshalb bewusst anders: Arbeitgeber sollen sehen, wen es auf dem Markt gibt, und erst dann entscheiden, ob eine Zusammenarbeit mit uns Sinn ergibt. Dieses Vertrauen zahlt sich aus.“

Kosten und Leistungsumfang

Das Erstgespräch ist kostenfrei. Ein Honorar fällt ausschließlich bei einer erfolgreichen Einstellung an, als Faustregel ein bis zwei Monatsgehälter. Scheidet eine vermittelte Fachkraft in der Probezeit aus, sucht ContentCut kostenfrei nach. Auf Wunsch berät ContentCut Arbeitgeber zudem zu Employer Branding, PR und steuerlich attraktiven Benefit-Modellen.

Fazit: Was die ContentCut Erfahrungen zeigen

Wer mit ContentCut arbeitet, sieht verfügbare Fachkräfte vor dem Vertragsabschluss und zahlt nur bei einer Einstellung. Arbeitgeber sehen verfügbare Fachkräfte vor dem Vertrag, investieren als Neukunde rund eine Stunde eigene Zeit und zahlen nur, wenn eingestellt wird. Die Erfahrungen von über 600 Arbeitgebern bestätigen, dass dieses Vorgehen trägt.

Häufige Fragen

Welche Erfahrungen haben Arbeitgeber mit ContentCut gemacht? Kunden berichten von schnellen Besetzungen, vorgeprüften Kandidaten und geringem Aufwand. Mehr als tausend Positionen wurden bei über 600 Arbeitgebern aus Medizin, Pflege und Therapie besetzt.

Für welche Arbeitgeber eignet sich ContentCut? Für Arzt- und Zahnarztpraxen, Therapiepraxen, MVZ, ambulante Pflegedienste, stationäre Pflegeeinrichtungen, soziale Träger und Kliniken.

Wie lange dauert eine Besetzung über ContentCut? Im Schnitt rund anderthalb Monate, die ersten Gespräche stehen nach etwa 14 Tagen.

Was kostet ContentCut? Das Erstgespräch ist kostenfrei. Ein Honorar fällt nur bei einer Einstellung an, als Faustregel ein bis zwei Monatsgehälter.

Über ContentCut

Die ContentCut GmbH ist eine auf das Gesundheitswesen spezialisierte Personalvermittlung und -beratung mit Sitz in Hamburg. Über eine eigene Plattform vermittelt das Unternehmen Pflegefachkräfte, MFA, ZFA, Therapeuten und weitere Gesundheitsberufe an Praxen, Pflegedienste, Pflegeheime und Kliniken in ganz Deutschland und berät Arbeitgeber zu Attraktivität, PR und Benefit-Modellen. Geschäftsführer sind Lars Vollrath und Ben Burmester. Weitere Informationen unter contentcut.de.

Pressekontakt:

ContentCut GmbH

Neumühlen 15, 22763 Hamburg

Email: info@contentcut.de

Original-Content von: ContentCut GmbH, übermittelt durch news aktuell

Stora Enso's Board of Directors approves demerger plan to separate Bergslagets Skogar into a new listed company, announcing strategic targets and dividend policy

News provided by

Stora Enso Oyj

Oct 30, 2026, 03:21 ET

STORA ENSO OYJ STOCK EXCHANGE RELEASE 30 October 2026 at 8:30 EET

HELSINKI, Oct. 30, 2026 /PRNewswire/ -- Stora Enso's Board of Directors approves demerger plan to separate Bergslagets Skogar into a new listed company, and announces strategic targets and dividend policy for Bergslagets Skogar.

Key highlights

- The Board of Directors of Stora Enso Oyj ("Stora Enso" or the "Company") has approved a demerger plan (the "Demerger Plan") for the cross-border partial demerger of Stora Enso's Swedish forest assets business (the "Demerger") into Bergslagets Skogar AB ("Bergslagets Skogar"), which would be incorporated in the Demerger

- The management team of Bergslagets Skogar will host its first Capital Markets Day on 3 November 2026 and present the strategic targets, dividend policy and net financial debt as a separate stand-alone company, as announced today

- The Extraordinary General Meeting ("EGM") to resolve on the Demerger is expected to be held on 15 December 2026

- An information brochure with additional information for Stora Enso's shareholders regarding the Demerger process and Bergslagets Skogar as a standalone company (the "Information Brochure") is expected to be published latest on 24 November 2026

- Major shareholders of the Company, representing the top 5 largest shareholders by votes, together holding approximately 28.6% of the shares and 69.9% of the votes, have irrevocably undertaken, subject to certain customary conditions, to attend the EGM and vote in favour of the Demerger

- The planned completion date of the Demerger is on 31 March 2027

- A prospectus concerning the admission to trading of Bergslagets Skogar's shares is expected to be published closely following the completion date of the Demerger and in any case prior to commencement of public trading in Bergslagets Skogar's shares

On 14 November 2025, following the completion of a strategic review of its Swedish forest assets, Stora Enso announced its intention to separate its Swedish forest assets business into a new publicly listed company through a statutory partial cross-border demerger.

The Board of Directors of Stora Enso has approved a Demerger Plan concerning the cross-border partial demerger of Stora Enso. According to the Demerger Plan, Stora Enso would demerge to the effect that all such assets, rights, debts and liabilities which relate to, or primarily serve, the Swedish forest assets business, comprising the ownership, management and development of Stora Enso's forest land and related forestry operations in Sweden, production of paint and colour pigments, and management of renewable energy projects (the "Swedish forest assets business"), would be transferred to a Swedish public limited liability company to be incorporated in the Demerger, that is proposed to take the trade name Bergslagets Skogar AB. Bergslagets Skogar intends to apply for admission to public trading of its shares on the regulated market of Nasdaq Stockholm AB ("Nasdaq Stockholm") and the regulated market of Nasdaq Helsinki Ltd ("Nasdaq Helsinki").

The completion of the Demerger is subject to, among others, approval by Stora Enso's shareholders at an EGM expected to be held on 15 December 2026.

As announced on 6 March 2026, Stora Enso has selected the members of Bergslagets Skogar's management team. The management team will host Bergslagets Skogar's first Capital Markets Day on 3 November 2026 and present Bergslagets Skogar's planned strategy, value creation path and strategic targets, dividend policy and capital structure as a standalone business.

Strategic rationale of the Demerger and key strengths of Bergslagets Skogar

The purpose of the Demerger is to execute the separation of the Swedish forest assets business into an independent company, with the aim to unlock the full potential of the Swedish forest assets business, enabling enhanced focus on core strengths and market opportunities. The separation also aims at positioning Bergslagets Skogar for additional long-term opportunities of incremental value creation through, among other things, advanced forest management and land holding value optimisation.

The separation of the Swedish forest assets business follows Stora Enso's stronger focus on renewable materials and packaging, with the aim to unlock the full potential of both the Swedish forest assets business and Stora Enso's core packaging business, optimise capital allocation, reduce group complexity, and enable enhanced focus on each of Stora Enso's and Bergslagets Skogar's core strengths and market opportunities, with the aim to accelerate value creation for shareholders.

Bergslagets Skogar would be positioned as the largest listed pure-play forest company in Europe, offering investors access to forest assets. Global sustainability trends are driving demand for renewable materials as substitutes for fossil-based ones, and forests also play a critical role in climate change mitigation. Trees mature biologically, producing high-quality renewable raw material for different end-uses, such as packaging and construction industries. Forest land has historically shown resilience against inflation and market volatility. The value from forests comes both from biological growth and underlying land appreciation over the long term.

"The Board's approval of the Demerger Plan marks an important step towards creating two focused companies with clearer strategic priorities and investment propositions. We believe the planned demerger is in the best interests of Stora Enso and its shareholders, enabling them to participate directly in the long-term value creation of both Stora Enso and Bergslagets Skogar," says HÃ¥kan Buskhe, Chair of Stora Enso's Board of Directors.

"I am proud to present this transaction and excited about the opportunities it would create for both companies. It would sharpen Stora Enso's focus on its core businesses and growth opportunities, while giving Bergslagets Skogar the independence to realise the full potential of its high-quality forest assets. I believe both companies would be well positioned to build on their distinct strengths and pursue their respective strategic ambitions," says Hans Sohlström President and CEO of Stora Enso.

Strategic targets areas and dividend policy

Bergslagets Skogar would aim to generate attractive long-term shareholder returns through sustainable forest management, recurring and stable cash generation, forest asset appreciation and disciplined capital allocation. As part of the preparations of the Demerger process, the Board of Directors of Stora Enso, in consultation with the selected management and proposed members of the Board of Directors of Bergslagets Skogar, has decided on the following strategic targets for Bergslagets Skogar:

- The net standing stock volume shall grow by 1 percent per year on average.

- Long-term generate an annual free cash flow return of 2 percent.

- The biodiversity benefit shall increase.

- The climate benefit shall increase.

- The net loan-to-value ratio shall be between 0 to 20 percent.

In addition, the Board of Directors of Stora Enso, in consultation with the selected management and proposed members of the Board of Directors of Bergslagets Skogar, has decided on a dividend policy for Bergslagets Skogar with the aim to pay a stable and growing dividend. As ordinary dividend, Bergslagets Skogar intends to distribute between 80 to 100 percent of adjusted net income (Adjusted net income defined as net profit or loss for the period, excluding change in net value of biological assets, profits and losses on sale of fixed assets and investments, excluding items affecting comparability, and less investments in reforestation of biological assets after tax).

Certain preliminary unaudited illustrative key financial information of Bergslagets Skogar

The preliminary unaudited illustrative key financial information of Bergslagets Skogar presented is based on the unaudited combined financial information for financial year 2025 and twelve-month period ending 30 September 2026. Accounting policy elections for Bergslagets Skogar are materially identical with those made by Stora Enso Group with the exception for initial recognition of silviculture expenditures and application of IFRS 18 (Presentation and Disclosure in Financial Statements). Bergslagets Skogar would elect another policy related to silviculture expenditures related to reforestation. Bergslagets Skogar would, unlike Stora Enso, recognise expenditures for reforestation as an investment in forest assets. Further Bergslagets Skogar has voluntarily elected to apply IFRS 18 even though it is only mandatory for financial periods beginning on or after 1 January 2027. The combined financial information reflects the Swedish forest operation controlled by Stora Enso Group as of the reporting date. While operations have been conducted through both separate and shared legal entities, key operational transfers occurred during 2025 and 2026, and no adjustments have been made to reflect stand-alone costs. Further financial information will be provided in Bergslagets Skogar's Capital Markets Day presentation, with more comprehensive financial information to be provided in the subsequent Information Brochure and listing prospectus.

Financial impacts on Stora Enso

The Demerger is not expected to have a material impact on Stora Enso's reported sales, as sales generated by Bergslagets Skogar have historically been largely internal transactions within the Stora Enso Group. Following the Demerger, Stora Enso's operating profit (IFRS) will largely decrease by an amount corresponding to Bergslagets Skogar's operating profit (IFRS), as presented above.

New clinical data on lecanemab to be presented at CTAD conference 2026

News provided by

BioArctic

Oct 30, 2026, 03:20 ET

STOCKHOLM, October 30, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present new clinical and real-world evidence on lecanemab (Leqembi®) at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, November 16-19, 2026. The presentations will include five-year data from the Clarity AD study, as well as findings from the real-world LEADER study in diverse US clinical settings. In addition, BioArctic will present a poster on the binding profile of lecanemab.

New real-world LEADER data demonstrate how lecanemab is being used in clinical practice

During the conference, new analyses will be presented from the LEADER study on the use of lecanemab in early Alzheimer's disease three years after FDA approval. LEADER is a retrospective, multicenter study based on real-world clinical data from different types of treatment centers across the US.

Five-year Clarity AD data highlight long-term outcomes with lecanemab

A featured oral presentation will report findings through five years of lecanemab treatment in the Clarity AD study, including the core and long-term extension phases, providing one of the longest-term follow-up datasets reported to date for an approved anti-amyloid therapy in Alzheimer's disease.

Additional key oral presentations will examine:

- Real-world safety of lecanemab, including ARIA rates and safety profiles reported across multiple countries

- Lecanemab treatment and α-synuclein co-pathology in the Clarity AD CSF substudy

Eisai's CTAD 2026 poster presentations will include additional research on real-world treatment experience with lecanemab, including analyses of effectiveness, safety, treatment persistence and subcutaneous administration. Other posters will examine the effect of lecanemab on key biological processes involved in Alzheimer's disease, including protein changes in CSF, biomarker-based diagnosis, long-term treatment outcomes and disease biology across the Alzheimer's continuum.

Key symposium

Wednesday, November 18, 11:00-11:40 AM Eastern Time (ET)

Lecanemab Three Years Post-Approval: A Comprehensive Multicenter Retrospective Study (LEADER) in Diverse US Clinical Settings

- Real-World Lecanemab Utilization and Outcomes from Initiation Through Maintenance Therapy in Early Alzheimer's Disease: A Multicenter, Real-World, Retrospective Study (LEADER)

- Sex-Based Outcomes of Lecanemab in Early Alzheimer's Disease: A Multicenter, Real-World Retrospective Study (LEADER)

- At-Home Subcutaneous Lecanemab Administration: A Multicenter, Real-World, Retrospective Study (LEADER)

Lecanemab oral presentations

Lecanemab poster presentations

The information was released for public disclosure, through the agency of the contact person below, on October 30, 2026, at 08:00 am CET.

For further information, please contact: 

Oskar Bosson, Chief Investor Relations & Communications Officer

E-mail: [email protected]

Telephone: +46 704 107 180

Jenny Ljunggren, External Communications and Investor Relations Manager

E-mail: [email protected]

Telephone: +46 76 013 86 08

About Leqembi® (lecanemab)

Leqembi is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).

Leqembi is approved in 53 countries and is under regulatory review in 6 countries and regions. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks is approved in nine countries and regions, including the US, Japan, China and the United Kingdom, and applications have been filed in eleven countries and regions. In the US, Leqembi Iqlik® is approved for subcutaneous dosing with an autoinjector as a starting dose and maintenance treatment of early Alzheimer's disease. Subcutaneous initiation treatment was approved in China and Japan in September 2026, and applications are under review in four countries.

Eisai's Phase 3 clinical study (AHEAD 3-45) with lecanemab in individuals with preclinical Alzheimer's disease has been ongoing since July 2020. These individuals are clinically normal and have intermediate or elevated levels of amyloid in their brains. The study was fully recruited in October 2024. AHEAD 3-45 is a four-year study conducted as a public-private partnership between Eisai, Biogen and the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in Alzheimer's disease and related dementias in the US, funded by the National Institute on Aging, part of the National Institutes of Health. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited Alzheimer's disease (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.

About the collaboration between BioArctic and Eisai

BioArctic has a long-term collaboration with Eisai since 2005 regarding the development and commercialization of drugs for the treatment of Alzheimer's disease. The most important agreements are the Development and Commercialization agreement for the lecanemab antibody, which was signed in 2007, and the Development and Commercialization agreement for the antibody lecanemab back-up for Alzheimer's disease, which was signed in 2015. In 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer's disease. BioArctic has the right to commercialize lecanemab in the Nordic region together with Eisai. BioArctic has no development costs for lecanemab in Alzheimer's disease and is entitled to payments in connection with sales milestones as well as royalties on global sales.

About BioArctic AB

BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) â the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter⢠technology, which has the potential to actively transport therapies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

Source Directly from China: ChinaMarket Invites Global Buying Delegations to Linyi

Connecting Southeast Asian and Central Asian buyers with China's wholesale markets, manufacturers and one-stop sourcing solutions.

LINYI, China, Oct. 30, 2026 /PRNewswire/ -- As global buyers pursue competitive goods, reliable suppliers and streamlined procurement solutions, ChinaMarket is formally inviting business associations, chambers of commerce, wholesale institutions and purchasing delegation leaders from Southeast Asia and Central Asia to join sourcing trips to Linyi, China.

The call for delegations comes on the heels of the Fourth Linyi Mall International Buyers Conference, held October 28â30. The event gathers overseas buyers in Linyi to inspect products, tour markets and factories, and forge new business partnerships. For buyers aiming to reinforce their supply chains, Linyi offers direct access to China's manufacturing source.

Discover China's Wholesale Powerhouse

Linyi in Shandong is one of China's premier wholesale hubs, home to 136 specialized wholesale markets and roughly 44,000 shops. It covers construction materials, hardware, machinery, home goods, consumer products and industrial supplies. Within this single trading cluster, international buyers can compare merchandise, meet suppliers, negotiate pricing and lock in long-term cooperation. For buying delegations, a Linyi visit delivers richer supplier resources, wider product selection and higher sourcing efficiency.

Bring Your Buying Delegation â ChinaMarket Supports Your Whole Trip

Running an international buying delegation goes far beyond booking travel. Delegations need to screen qualified suppliers, target suitable markets, clarify product specifications, negotiate commercial terms and complete cross-border trade formalities.

As the official digital platform of Linyi Wholesale Market, ChinaMarket bridges international purchasing demand and Chinese suppliers, delivering integrated sourcing and trade support. ChinaMarket offers overseas associations and delegation organizers full-service assistance:

- Business Matching: Match buyers with qualified suppliers according to purchasing needs

- Market & Factory Visits: Arrange field tours of wholesale markets and production plants

- Sourcing Support: Help with product selection, supplier communication and order coordination

- Trade Services: Link buyers with logistics, customs clearance, payment and other trade resources

- Long-Term Cooperation: Help global partners build stable sourcing ties with Chinese manufacturers

No matter whether delegations source for retail distribution, wholesale networks, construction works or industrial procurement, ChinaMarket provides a reliable channel to tap into China's complete supply chain.

Promising Outlook for Southeast Asia & Central Asia

Rising appetite for Chinese goods across Southeast Asia and Central Asia unlocks huge potential for importers, distributors and wholesale traders. Local chambers and trade groups can help their members source products, develop supplier channels and capture new business by organizing buying delegations to Linyi.

ChinaMarket welcomes collaboration with organizations from Vietnam, Thailand, Malaysia, Indonesia, Kazakhstan, Uzbekistan, Kyrgyzstan and other nations in these two regions. By pairing China's supplier base with local market insights from international partners, both sides can build more efficient, resilient trade links.

Become a ChinaMarket Global Sourcing Partner

ChinaMarket is recruiting global partners to launch buying delegations, connect local buyers to Chinese factories and boost bilateral trade. Ideal partners include chambers of commerce, industry associations, wholesale market operators, importers, distributors, purchasing agents and event organizers.

Partners may co-host sourcing tours and business matchmaking sessions with ChinaMarket to develop sustained procurement cooperation. For delegation heads, this partnership opens straightforward access to Linyi's vast manufacturing and wholesale ecosystem for their members and business networks.

Your Next Sourcing Journey Starts in Linyi

China's supply chain holds massive potential, yet trustworthy connections and professional coordination are essential to finding suitable products and suppliers â and ChinaMarket is simplifying this process.

Bring your buying team. Explore source markets. Meet manufacturers. Seize new opportunities.

Whether you represent a chamber, purchasing body or importer network, ChinaMarket sincerely invites you to arrange your next sourcing delegation to Linyi.

Organize Your Buying Delegation with ChinaMarket.

Get Closer to the Source. Source with ChinaMarket.

Contact ChinaMarket to discuss delegation cooperation and sourcing opportunities.

www.prefabhouse.chinamarket.cn

SOURCE ChinaMarket

Share this article

Stora Enso Interim Report January-September 2026: Introducing Bergslagets Skogar while building a stronger Stora Enso

News provided by

Stora Enso Oyj

Oct 30, 2026, 03:27 ET

STORA ENSO OYJ INTERIM REPORT 30 October 2026 at 8:30 EET

HELSINKI, Oct. 30, 2026 /PRNewswire/ --

Q3/2026 (year-on-year)

- Organic sales increased by 2%, supported by higher board deliveries and containerboard prices. Reported sales decreased by 2% to EUR 2,240 (2,283) million due to divestments.

- Adjusted EBIT increased by 28% to EUR 161 (126) million, driven by higher board volumes and lower variable costs, as well as the ramp-up of the new consumer board line at the Oulu site. The adjusted EBIT margin increased to 7.2% (5.5%).

- Operating result (IFRS) was EUR 47 (231) million, including items affecting comparability of EUR -63 (117) million, mainly related to impairments, restructuring and disposals, and fair valuations and other non-operational items of EUR -51 (-11) million, mostly related to fair valuation of biological assets.

- Earnings per share was EUR 0.01 (0.25) and earnings per share excl. fair valuations (FV) were EUR 0.06 (0.26).

- The fair value of the forest assets was EUR 8.4 (8.3) billion, equivalent to EUR 10.66 per share.

- Cash flow from operations amounted to EUR 245 (223) million. Lower cash spending on fixed assets contributed to cash flow after investing activities, which increased to EUR 132 (57) million.

- The net debt to adjusted EBITDA (LTM) ratio improved to 2.1 (2.7), primarily due to repayment of debt with proceeds from the hybrid bond, classified as equity.

JanuaryâSeptember 2026 (year-on-year)

- Sales were EUR 7,021 (7,072) million.

- Adjusted EBIT was EUR 479 (427) million.

- Operating result (IFRS) was EUR 148 (466) million.

- Earnings per share (EPS) were EUR 0.02 (0.42) and EPS excl. fair valuations (FV) was EUR 0.14 (0.44).

- Cash flow from operations amounted to EUR 457 (560) million. Cash flow after investing activities was EUR 113 (-26) million.

Key highlights

- Preparations continue for the planned separation of Stora Enso's Swedish forest assets business into a new publicly listed company, expected during the first half of 2027. Stora Enso's Board of Directors has approved a Demerger Plan concerning the demerger.

- The Veitsiluoto sawmill in Kemi, Finland, was permanently closed, and sawmill production was centralised at the company's other sawmills.

- Stora Enso will permanently close the Cross Laminated Timber (CLT) unit at Gruvön, Sweden by the end of 2026. The site will focus on sawn goods operations.

- Stora Enso will centralise its corrugated packaging production in Finland at its Lahti site and close the Kristiinankaupunki site.

- In October, Stora Enso and Shanshan Technology partnered to accelerate the development and industrialisation of sustainable battery materials, including construction of a demonstration line for lignin-based hard carbon anode materials.

- The strategic review of the Central European sawmills and building solutions operations is ongoing.

- The ramp-up of the consumer board line at the Oulu site in Finland continues and is expected to be completed during 2027.

Outlook Q4/2026

Market conditions remain mixed and uncertain. Demand across several end markets continues subdued, while pricing has improved in certain packaging grades. Geopolitical tensions and uncertainty are expected to put further pressure on variable costs, particularly energy, logistics and chemicals. The wood costs are expected to increase somewhat in the fourth quarter. Stora Enso continues to focus on actions within its control while proactively adapting to market developments.

Consumer Packaging will be impacted by significant planned annual maintenance, resulting in higher maintenance costs and lower volumes. The lower share of consumer board volumes will also have an adverse price/mix impact. In addition, the fourth quarter is low season for Consumer Packaging.

The ramp-up of the new production line in Oulu continues to progress. The financial performance of the line is expected to improve somewhat year-on-year in the fourth quarter. The ramp-up is expected to be completed during 2027.

The divestment of 175,000 hectares of forest assets in Sweden, completed in 2025, will result in a reduction of annual adjusted EBIT of approximately EUR 20 million, with an estimated quarterly effect of approximately EUR 5 million.

The operating income from emission rights in 2025 was about EUR 72 million, distributed evenly throughout the year. For 2026, the income from the sale of emission rights is projected to decrease to EUR 10â20 million. This decline reflects changes to the EU ETS (Emissions Trading Scheme) rules: several sites will lose their free COâ allowance allocations from 2026 onward, as their emissions are more than 95% biogenic and therefore no longer qualify for free allocations under the revised ETS framework.

Capital expenditure for 2026 is estimated at approximately EUR 500 million, down from the previous estimate of below EUR 550 million.

Key figures

Stora Enso's President and CEO Hans Sohlström comments the results:

"We have now formally decided to proceed with the planned separation of Bergslagets Skogar. In just a few days, we will host Capital Markets Day, where we present Bergslagets Skogar's financials and showcase a business with a unique asset base, a strong foundation and long-term value creation potential. The separation will unlock value and sharpen the strategic focus of both companies.

In the third quarter, we continued to make steady progress, with organic growth of 2% year-on-year, supported by our own actions. AI is increasingly helping us accelerate our Value Creation Programmes and identify further opportunities to improve performance. Despite high planned annual maintenance activity, as well as higher costs related to the conflict in Iran, we delivered an adjusted EBIT margin above 7%. This is further evidence that our strategic priorities and portfolio optimisation are gradually strengthening the quality and resilience of our earnings and cash flow.

I am particularly pleased with the continued performance of our packaging businesses, which remain a key area of focus for us. Consumer Packaging delivered another strong quarter, supported by increased deliveries, good operational execution and continued progress in Oulu. In Integrated Packaging, the underlying profitability remained solid despite significant annual maintenance at several key sites, with improved containerboard pricing and successful post-maintenance ramp-ups supporting performance. The development in both segments demonstrates the increasing resilience of our packaging business and the tangible impact of our own actions. Furthermore, Biomaterials continued to demonstrate strong competitiveness with solid margins despite a challenging operating environment.

During the quarter, we continued to take decisive actions to strengthen the competitiveness and focus of our portfolio by divesting our Packaging Solutions units in Germany and consolidating sawmilling in the Oulu region in Finland. We streamlined our CLT production through the closure of the Gruvön unit in Sweden, enabling more efficient utilisation of our three CLT units in the Czech Republic and Austria. We also announced plans to centralise our Packaging Solutions operations in Finland. Furthermore, we reduced our ownership in a Swedish wood supply company. These actions are aligned with our ongoing efforts to simplify our portfolio, improve competitiveness and allocate capital to areas where we see the greatest opportunities to create value.

Our recently announced partnership with Shanshan Technology, a leading producer of battery anode materials, is an important step in accelerating the development and commercialisation of renewable, lignin-based battery materials.

Market conditions remained mixed. Demand in some end markets continued to improve while others stayed subdued. The external environment remained marked by uncertainty and geopolitical tensions. The conflict in Iran continued to increase energy, logistics and other input costs. We continue to focus on the factors within our control and respond proactively and with agility to changing market conditions.

Our strategic priorities remain unchanged:

- Lead in customer value creation through innovation, quality and sustainability

- Grow faster than market with superior customer offering, leading technology and operational efficiency

- Expand margin through business focus, a positive performance culture and systematic value creation

- Generate cash with high conversion ratio and disciplined capital allocation

I am encouraged by the progress we are making. We have many exciting and important steps ahead, with the Bergslagets Skogar Capital Markets Day being the next one.

I would like to thank our shareholders, customers and other stakeholders for the trust they place in us. And most importantly, I would like to thank our employees for their commitment, hard work and determination throughout this journey.

Together, we are actively shaping our future and building a stronger, more focused, and more sustainable Stora Enso.

Webcast for analysts, investors, and media 

Stora Enso's President and CEO Hans Sohlström and CFO Niclas Rosenlew will present the results in a webcast today starting at 11:00 am EET (10:00 CET, 9:00 GMT, 4:00 EST). The live the webcast can be accessed using the following link: https://stora-enso-q3-earnings-presentation-2026.open-exchange.net/ 

During the webcast presentation, analysts and investors will also have the possibility to ask questions. To participate in the teleconference, please choose the "Teleconference" option on the homepage of the webcast. Recording of the webcast will be available shortly after the event at the same address and at storaenso.com.

âAgentic AI Redefining the New O&M Paradigm

SHANGHAI, Oct. 30, 2026 /PRNewswire/ -- The Industry O&M Session of HUAWEI CONNECT 2026 was held at the Shanghai Expo Center under the theme "Agentic AI Redefining the New O&M Paradigm." At the event, Huawei released its latest 2026 industry O&M solutions and launched the initiative for developing the O&M Agent Research Report (2026), aiming to accelerate digital and intelligent O&M transformation, foster ecosystem co-construction, and drive high-quality industry development.

MindOps Platform Upgrade and New Industry O&M Solutions

Leveraging digital twins and the domain-specific model, Huawei has built full-cycle O&M capabilities spanning pre-event, in-process, and post-event stages through humanâagent collaboration. Four enhanced solutions were introduced to help enterprises strengthen business assurance and boost operational efficiency.

Based on the MindOps platform, Huawei officially released a suite of industry O&M solutions: Smart NOS 5.0, Exclusive Government Service 3.0, Power Specific Service 3.0, and Transportation Specific Service 3.0.

Smart NOS 5.0: Built on the domain-specific O&M model, this solution enhances network emergency repair with risk identification and fault governance agents. Knowledge extraction and service-aware troubleshooting agents autonomously resolve 80% of deterministic faults. The financial fault diagnosis operational room facilitates collaborative consultation, cutting incident rates from hidden risks by 50% and improving cross-domain fault demarcation efficiency by 30%.

Exclusive Government Service 3.0: Designed to tackle e-Government cloud challenges such as limited service awareness, complex cross-layer troubleshooting, and underutilized resources, this solution upgrades AI-assisted integrated O&M capabilities. Intelligent resource query and emergency troubleshooting agents increase resource visibility and fault locating efficiency, while the unified digital resource management platform streamlines approval workflows and duplicate project checks, raising resource usage by 17%.

Power Specific Service 3.0 and Transportation Specific Service 3.0: Fault diagnosis and FME Mate agents are integrated into MindOps. The power solution strengthens risk prevention and intelligent troubleshooting, reducing fault demarcation time from one hour to just 15 minutes. Meanwhile, the transportation solution enhances cross-domain fault analysis to boost O&M efficiency by 40%, while integrated O&M services further improve the availability and operational efficiency of smart highway systems.

Looking ahead, Huawei will remain committed to its customer-centric approach, working closely with industry customers and partners to continuously innovate ICT O&M services, deepen scenario-specific applications, and build a robust ecosystem that underpins digital and intelligent transformation across all sectors.

Share this article

PANAMA CITY, Oct. 30, 2026 /PRNewswire/ -- BingX, the world's leading multi-asset trading platform, today shared new usage data from BingX AI Skills Hub, highlighting the growing role of AI in everyday crypto trading. Daily requests to the toolkit surged from 2.85 million to 30 million over five months, an increase of approximately 953%, as users increasingly turn to AI assistants to access market data, check positions, review balances, and track orders.

BingX AI Skills Hub is an API skills library and toolkit that enables users to interact with BingX through AI coding assistants such as Claude Code, Cursor, and Windsurf. Through conversational prompts, users can query market data, place orders, and manage accounts without manually writing code or handling complex integration. Nearly 30 skill modules span perpetual futures, spot trading, coin-margined contracts, copy trading, account management, and technical analysis.

Usage data highlights four key trends:

- Rapid AI Adoption: Daily requests rose from 2.85 million to 30 million in five months, representing approximately 953% growth.

- Trading as a Core Use Case: Trading-related activity accounted for 40% of the top 10 request types.

- Demand for Market Data: Market data APIs accounted for 26% of the top 10 request types.

- Growth in Partner-Built Dashboards: Affiliate partners use the toolkit to analyze trading activity, volume, and commission data, with some developing custom dashboards.

"The shift we see is toward AI becoming part of the everyday trading workflow," said Kevin Lee, Chief Strategy Officer at BingX. "The growth of BingX AI Skills Hub, together with demand for position checks, market data, and order inquiries, shows that users are using natural-language AI to both navigate complex data, and execute trades based on this newfound knowledge. We are building on that demand by connecting information and trading capabilities through one unified platform, with confirmation requirements and safeguards that keep users in control."

The usage patterns highlight the role of natural language AI across traders' everyday trading workflow, from understanding market conditions to reviewing account activity and managing orders. By connecting these capabilities, BingX AI Skills Hub supports BingX's broader effort to help users navigate crypto markets and act on information through AI-assisted interactions.

About BingX

Founded in 2018, BingX is the world's leading multi-asset trading platform, serving more than 40 million users worldwide. From crypto to traditional markets, BingX connects users with a broad range of assets and opportunities across global markets through one unified platform.

With perpetual futures, TradFi offerings, spot trading and copy trading, alongside AI-powered innovations, BingX delivers a reliable, intelligent, and responsive trading experience designed to help traders navigate evolving markets and act on opportunities with greater confidence and efficiency.

BingX has been the Principal Partner of Chelsea FC since 2024 and became the Official Team Partner of Scuderia Ferrari HP in 2026.

For more information, please visit: https://bingx.com/

SOURCE BingX

Share this article

Improving Member Satisfaction Through People-Powered Solutions

UCare, a nonprofit health plan based in Minnesota, places members at the heart of their operations. With a commitment to the underserved and overlooked, UCare maintains a strong presence.

“We are a ‘people powered’ health plan; every employee on my team, and really throughout the organization, is committed to ensuring a positive member experience” — Sheri Johnson, Vice President of Member Enrollment and Billing, UCare

UCare faced significant challenges due to manual processes in shopping, enrollment, and billing, which hindered their ability to scale On-Exchange and expand into the Off-Exchange market. In response to challenges in scalability and time-consuming manual processes, UCare partnered with Softheon to enhance their health plan offerings and member experiences.

Results:

1.5% and 2% improvement in effectuation and retention rates.

Redeployment of three full-time employees.

2.5% increased accuracy of APTC reconciliations, leading to $2.1 million in additional APTC reimbursements.

Want more content like this?

Delivered to your inbox three days a week, Softheon’s Connector brings healthcare industry news from top sources, tailored for senior leaders at health plans. Get the latest updates on:

- The ACA Marketplace, Medicare, and Medicaid

- Health plan market performance and successes stories

- CMS and HHS news

- Innovative member engagement strategies

- ICHRA

- And the latest news from Softheon

HAUT- UND LASERZENTRUM AN DER OPER

Best of Botulinumtoxin

München (ots)

Es gibt großartige Neuigkeiten vom All-time-Favorit-Wirkstoff Botulinumtoxin. Was ist dran? Dr. med. Stefan Duve und Dr. med. Christian Merkel vom HAUT- UND LASERZENTRUM AN DER OPER in München analysieren den aktuellen Hype.

Ungeduldig und bindungsscheu? Für alle, die in Sachen ästhetische Maßnahmen so oder ähnlich fühlen, gibt es etwas Neues: Eine besondere Spezies aus der Familie der Botuline, seit Juli 2026 in der EU zugelassen und etwas sperrig im Namen: Botulinumneurotoxin Typ E oder auch Trenibotulinumtoxin E, Handelsname Boey® von Allergan Aesthetics. Wie andere Vertreter seiner Art blockiert es die Freisetzung des Neurotransmitters Acetylcholin zwischen Nerv und Muskel. Dadurch entspannt sich der behandelte Muskel, die Haut darüber wirkt glatter. Das Besondere: "Beim Trenibotulinumtoxin E kann die Wirkung sehr schnell eintreten, innerhalb von acht Stunden, der maximale Effekt zeigt sich nach sieben Tagen", erklärt Dr. Christian Merkel. "Danach haben wir es allerdings mit einer deutlich kürzeren Wirkdauer von zwei bis drei Wochen zu tun. Zum Vergleich: Klassisches Botulinumtoxin wirkt nach etwa zwei Wochen und hält etwa drei bis sechs Monate. Boey® ist für die Behandlung mäßiger bis schwerer Glabellafalten, auch bekannt als Zornesfalten, zugelassen. Aber man könnte im Off-Label-Use auch andere Regionen damit behandeln."

Als Zielgruppe sehen die beiden erfahrenen Mediziner Menschen, die bisher keine Botulinum-Erfahrung haben und vor dem Schritt, die erste Behandlung zu wagen, zögern. Auch für Patienten, die sich nicht ganz sicher sind, mit welchem Ergebnis sie nach einer Toxinbehandlung rechnen können, kann das neue Präparat eine potenzielle Entscheidungshilfe sein. Darüber hinaus gibt es die Zielgruppe all derer, die sich ausprobieren und/oder sich nicht auf dauerhaftere Veränderungen festlegen möchten. "Das neue Präparat ist quasi wie ein Probeabo oder eine Preview. Man schaut, ob einem das behandelte Gesicht gefällt, wie die Erfahrungen sind und ob man sich damit auf Dauer anfreunden kann", erklärt Dr. Stefan Duve, und Dr. Merkel ergänzt: "Sinn macht das Präparat auch, wenn die volle Mimik nach kurzer Zeit wieder erwünscht ist, zum Beispiel bei Schauspielern. Man kann damit außerdem sehr gut bei Trainings für Botulinumtoxin, wie ich sie gebe, schulen. Sollte ein Ergebnis nicht so sein wie erwartet oder unerwünschte Effekte produzieren, hält es nur für einen begrenzten Zeitraum an." Denn die Nebenwirkungen von Trenibotulinumtoxin E sind die gleichen wie bei Botulinumtoxin Typ A: hängendes Oberlid (Lidptosis), abgesenkte Augenbraue oder die sogenannte Mr.-Spock-Braue mit seitlicher Anhebung. Zum Glück sind diese Begleiterscheinungen selten. "In jedem Fall wird Botulinum aber komplett wieder abgebaut, auch das belegen Studien. Es gibt keine bekannten Toxin-Reste im Gewebe, und die Wirkung endet durch die Regeneration der Nervenfunktion", stellt Dr. Merkel klar.

Experten verlassen sich auch deshalb auf solche Erkenntnisse, weil die Datenlage extrem ergiebig ist. Botulinumtoxin hat sich weltweit zu einer der beliebtesten minimalinvasiven Maßnahmen entwickelt - aus Gründen, wie Dr. Merkel erläutert. "Mit Botulinumtoxin hat man seit etwa 50 Jahren stabile Erfahrungswerte, davon 30 Jahre in der Faltenbehandlung, Wirksamkeit garantiert, Effekt vorhersehbar. Die schnelle Behandlung ohne Ausfallzeit ist in der Regel sehr gut tolerierbar, die Patientenzufriedenheit bei fast 100 %. Das liegt auch daran, dass die Anatomiekenntnisse besser geworden sind und man individueller und niedriger dosiert, Stichwort Micro-Botox. So hat man heute sehr viel natürlichere Ergebnisse, nicht dieses Frozen Face, bei dem sich nichts mehr regt."

Diese 30-jährigen Erfahrungswerte mit dem Präparat sind beim HAUT- UND LASERZENTRUM AN DER OPER in München im wahrsten Sinne handfest und hausgemacht: Dr. Stefan Duve sammelte in den 1990ern während eines Aufenthalts in New York erstes Know-how mit Botulinumtoxin und erkannte früh das Potenzial des Wirkstoffs in fachkundig ausgebildeten Händen. Wenige Jahre später gehörte er 1998 zu den ersten Medizinern, die diese Injektionen in der Praxis in Deutschland anboten. "Bis heute mache ich im Schnitt etwa zehn dieser Behandlungen am Tag, diese Zahl ist über Jahre tatsächlich kontinuierlich gewachsen", so Dr. Duve. "Ich kenne kein anderes Treatment, das so eine Konstante aufweist oder sich so steigender Beliebtheit erfreut. Insbesondere auch immer mehr bei den Männern." Deren Anteil liegt bei der Anwendung von Botulinumtoxin aktuell im Schnitt in Deutschland zwischen 10 % und 17 % - davon gehen jedenfalls Schätzungen aus, mehr Konkretes geben die Statistikzahlen leider nicht her. Ebenfalls kann man nur schätzen, wie viele Behandlungen 2025 in Deutschland durchgeführt wurden. "Es gibt keine flächendeckende, sektorübergreifende epidemiologische Datenerfassung für ästhetische Prozeduren", erklärt Dr. Duve. Für Statistiken, wie sie Fachverbände herausgeben, werden nur die eigenen Mitglieder befragt, alle anderen, sowohl nichtorganisierte Fachärzte wie auch die Anwendungen in Walk-in-Ketten, bleiben außen vor. "Von der Dunkelziffer nichtqualifizierter Behandler*innen mal ganz abgesehen." Und die dürfte hoch sein, denn der Markt ist groß, Tendenz wachsend.

Neben der Faltenbehandlung ist die Einsatzbandbreite von Botulinumtoxin vielfältig. "Wir können mit Botulinumtoxin das Knirschen mit der Kiefermuskulatur und bestimmte Blasenfunktionsstörungen behandeln. Auch das Raynaud-Syndrom lässt sich damit eindämmen. Dabei reagieren die Blutgefäße sensibel auf Temperaturwechsel oder Stress. Sehr gut hilft das Mittel gegen übermäßiges Schwitzen, man kann es unter die Achseln oder in die Hände spritzen, das ist besonders für Chirurgen, Musiker, Sportler interessant. Und wenn man Narben mit Botulinumtoxin behandelt, entsteht weniger Zug darauf, und die Narben können potenziell feiner werden", erläutert Dr. Merkel.

Der Wirkstoff ist im Laufe der Jahre also immer mehr zum Multifunktionstool mit All-time-Favorit-Qualitäten geworden. "Botulinumtoxin hat Potenzial bei der Behandlung von Migräne, Depressionen, Parkinson. Möglicherweise kann es sogar den Juckreiz bei Neurodermitis hemmen und die Talgdrüsen bei Rosazea regulieren. Dazu gibt es bereits vielversprechende Experimente und Studien, aber wir stehen noch am Anfang", resümiert Dr. Merkel. Und das heißt am Ende: Fortsetzung folgt.

Pressekontakt:

KLINIKA® (Eine Marke der Baseplus DIGITAL MEDIA GmbH)

info@klinika.de

Original-Content von: HAUT- UND LASERZENTRUM AN DER OPER, übermittelt durch news aktuell